Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis.

Napier J, Rose L, Adeoye O, Hooker E, Walsh KB.

Immunopharmacol Immunotoxicol. 2019 Feb;41(1):7-15. doi: 10.1080/08923973.2019.1566361. Epub 2019 Jan 31.

PMID:
30702002
2.

Current and future therapies for multiple sclerosis.

Minagar A.

Scientifica (Cairo). 2013;2013:249101. doi: 10.1155/2013/249101. Epub 2013 Feb 7. Review.

3.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

4.

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G.

Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381. doi: 10.1002/14651858.CD011381.pub2. Review.

PMID:
26384035
5.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
6.

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A.

J Cent Nerv Syst Dis. 2012 May 16;4:81-103. doi: 10.4137/JCNSD.S6692. Print 2012.

7.

2014 multiple sclerosis therapeutic update.

Cree BA.

Neurohospitalist. 2014 Apr;4(2):63-5. doi: 10.1177/1941874414525410.

8.

Update on disease-modifying therapies for multiple sclerosis.

Vargas DL, Tyor WR.

J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27. Review.

PMID:
28130412
9.

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.

Li H, Hu F, Zhang Y, Li K.

J Neurol. 2019 May 25. doi: 10.1007/s00415-019-09395-w. [Epub ahead of print] Review.

PMID:
31129710
10.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
11.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
12.

[Current immunotherapy of multiple sclerosis].

Paul F, Ruprecht K.

Nervenarzt. 2015 Aug;86(8):1031-42; quiz 1043-4. doi: 10.1007/s00115-015-4338-1. German.

PMID:
26253589
13.

Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis.

TaŞKapilioĞLu Ö.

Noro Psikiyatr Ars. 2018;55(Suppl 1):S15-S20. doi: 10.29399/npa.23402. Review.

14.

Multiple Sclerosis Therapies in Pediatric Patients: Challenges and Opportunities.

Jančić J, Nikolić B, Ivančević N, Henčić B, Samardžić J.

In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]. Brisbane (AU): Codon Publications; 2017 Nov 27. Chapter 3.

15.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

16.

Novel Agents for Relapsing Forms of Multiple Sclerosis.

Straus Farber R, Harel A, Lublin F.

Annu Rev Med. 2016;67:309-21. doi: 10.1146/annurev-med-052814-023415. Epub 2015 Sep 17. Review.

PMID:
26394285
17.

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M.

Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8. Review.

PMID:
27645339
18.

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O.

Clin Exp Immunol. 2014 Mar;175(3):397-407. doi: 10.1111/cei.12206. Review.

19.

Multiple Sclerosis: Immunopathology and Treatment Update.

Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J, Apostolopoulos V.

Brain Sci. 2017 Jul 7;7(7). pii: E78. doi: 10.3390/brainsci7070078. Review.

20.

Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.

Dashputre AA, Kamal KM, Pawar G.

J Manag Care Spec Pharm. 2017 Jun;23(6):666-676. doi: 10.18553/jmcp.2017.23.6.666.

Supplemental Content

Support Center